• Voronoi's Nov. 10, 2026, correction raised target enrollment for its Phase 1/2 VRN110755 lung cancer trial to approximately 355 from 255 patients.
• An updated protocol was submitted to Australia's Human Research Ethics Committee on Nov. 10, 2026, seeking a trial amendment.
• The trial targets patients with EGFR-mutated non-small cell lung cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Voronoi Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261110900724), on November 10, 2026, and is solely responsible for the information contained therein.